trial · primary record
sintilimab
Hepato Cellular Carcinoma (HCC)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 105 |
| Primary completion | 2028-03-19 |
| Primary endpoint | 1-year recurrence-free survival rate |
| Registry ID | NCT07487662 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:55.694Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07487662
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.